WHO ICTRP trial
A Phase 1 study of Eribulin Mesylate with Trastuzumab.
JPRN-jRCT2080221578 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080221578 |
|---|---|
| Public title | A Phase 1 study of Eribulin Mesylate with Trastuzumab. |
| Scientific title | A Phase 1 study of Eribulin Mesylate with Trastuzumab for Advanced or Recurrent Human Epiderma Growth Factor Receptor 2-Positive (HER2+) Breast Cancer. |
| Primary sponsor | Eisai Co., Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 1 |
| Conditions | Breast Cancer |
| Interventions | investigational material(s) Generic name etc : E7389 INN of investigational material : eribulin mesylate Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Injection |
| Registration date | Sep 13, 2011 |
| Target size | 24 |
| Secondary IDs | JapicCTI-111618 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: